Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin

This publication has 26 references indexed in Scilit:

• The Use of Prothrombin(S525C) Labeled with Fluorescein to Directly Study the Inhibition of Prothrombinase by Antithrombin during Prothrombin Activation
  Published by Elsevier ,2001
• A Kinetic Analysis of the Tissue Plasminogen Activator and DSPAα1 Cofactor Activities of Untreated and TAFIa-treated Soluble Fibrin Degradation Products of Varying Size
  Journal of Biological Chemistry, 2001
• Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties
  Published by Elsevier ,1998
• Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein)
  Journal of Biological Chemistry, 1997
• A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 Domain
  Journal of Biological Chemistry, 1997
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
  Published by Elsevier ,1996
• Reaction of human α₂‐antiplasmin and plasmin Stopped‐flow fluorescence kinetics
  FEBS Letters, 1996
• Activation and Characterization of Procarboxypeptidase B from Human Plasma
  Biochemistry, 1995
• Serpin-serine protease binding kinetics: .alpha.2-antiplasmin as a model inhibitor
  Biochemistry, 1991
• α2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin
  Biochemical and Biophysical Research Communications, 1988